Israel Englander Vertex Pharmaceuticals Inc Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 324,816 shares of VRTX stock, worth $148 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

324,816

Previous 105,800 207.01%

Holding current value

$148 Million

Previous $43 Million 215.41%

% of portfolio

0.06%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $130 Million - $142 Million	-317,934 Reduced 49.46%	324,816 $136 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $145 Million - $174 Million	-423,968 Reduced 39.75%	642,750 $262 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $333 Million - $373 Million	1,059,682 Added 15060.86%	1,066,718 $375 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $93.3 Million - $106 Million	-329,526 Reduced 97.91%	7,036 $2.22 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $95.2 Million - $107 Million	333,024 Added 9412.78%	336,562 $97.2 Million

Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $78.9 Million - $88 Million	-287,965 Reduced 98.79%	3,538 $1.02 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $5.08 Million - $6.33 Million	-21,633 Reduced 6.91%	291,503 $82.1 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $29.6 Million - $34.9 Million	-133,717 Reduced 29.92%	313,136 $81.7 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $44 Million - $55.6 Million	-248,855 Reduced 35.77%	446,853 $98.1 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $60.1 Million - $67.2 Million	331,296 Added 90.91%	695,708 $126 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $102 Million - $120 Million	-541,509 Reduced 59.77%	364,412 $73.5 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $123 Million - $143 Million	592,174 Added 188.74%	905,921 $195 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $55.8 Million - $74.4 Million	269,398 Added 607.45%	313,747 $74.2 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $27.3 Million - $32.3 Million	-106,592 Reduced 70.62%	44,349 $12.1 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $13 Million - $17.1 Million	57,693 Added 61.87%	150,941 $43.8 Million
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $60.8 Million - $75.5 Million	-304,556 Reduced 76.56%	93,248 $22.2 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $614,326 - $825,108	-3,685 Reduced 0.92%	397,804 $87.1 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $16.5 Million - $18.5 Million	-99,114 Reduced 19.8%	401,489 $68 Million
Q2 2019 Aug 15, 2019	SELL	$164.61 - $190.37 $133 Million - $153 Million	-805,130 Reduced 61.66%	500,603 $91.8 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $114 Million - $132 Million	695,522 Added 113.98%	1,305,733 $26.1 Million
Q1 2019 May 14, 2019	SELL	$163.73 - $194.7 $102 Million - $121 Million	-620,640 Reduced 50.42%	610,211 $112 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $33.8 Million - $42.8 Million	222,524 Added 22.07%	1,230,851 $204 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $57.8 Million - $66.4 Million	344,730 Added 51.95%	1,008,327 $194 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $13.9 Million - $16.2 Million	95,048 Added 16.72%	663,597 $113 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $100 Million - $117 Million	-659,534 Reduced 53.7%	568,549 $92.7 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $60.4 Million - $68.5 Million	-440,125 Reduced 26.38%	1,228,083 $184 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $247 Million - $271 Million	1,668,208	1,668,208 $254 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $117B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account